InDevR licenses FluChip influenza-diagnostics technology from University of Colorado
APRIL 29, 2009--InDevR (Boulder, CO) says it has licensed the University of Colorado's light-based FluChip technology. Professor Kathy Rowlen, who led a team of university researchers and scientists at the Centers for Disease Control and Prevention to co-develop the technology, says previous work indicates a version of the FluChip should be able to quickly distinguish human H1N1 viruses from the new "swine flu" H1N1 virus.
APRIL 29, 2009--The startup company InDevR (Boulder, CO) says it has licensed the University of Colorado's light-based FluChip technology. Professor Kathy Rowlen led a team made up of university researchers and scientists at the Centers for Disease Control and Prevention (CDC) to co-develop the technology in an NIH-sponsored effort. "The reader uses an LED array and a CMOS camera," Rowlen told BioOptics World.
Rowlen, now the CEO of InDevR, said the company has arranged to test genetic material from the recent swine H1N1 virus on the MChip as well as other versions of the FluChip now under development. "Based on work we conducted a couple of years ago, it appears that the M-gene version of the FluChip will be able to distinguish human H1N1 viruses from the new swine H1N1 virus," Rowlen said. "If that proves to be the case, the FluChip will be a much-needed and powerful new tool for surveillance since all of the current influenza diagnostics on the market are unable to subtype this virus."
The most popular diagnostic tests for influenza include rapid immunoassays, which are only able to identify the type (A or B) of influenza virus, and reverse-transcriptase polymerase chain reaction (PCR) assays, which were designed for human-adapted influenza viruses and are not able to identify the swine H1N1 subtype.
State Public Health Laboratories must now send any influenza A viruses that cannot be subtyped using existing diagnostics to the CDC for analysis by genome sequencing or viral isolation. The CDC must select viruses to analyze since it is not possible to run every sample collected from a large number of Public Health Labs.
The M-gene based FluChip has been demonstrated to delineate human-adapted viruses from non-human viruses, such as the H1N1 virus that caused the 1918 "Spanish Flu". "Since the FluChip assay can be conducted within a single day it could be employed in State Public Health Laboratories to greatly enhance influenza surveillance and our ability to track the virus," Rowlen said.
InDevR will combine the FluChip technology with an innovative detection technology (NESATM), which InDevR also licensed from the University of Colorado and further developed with NIH sponsorship, to make the FluChip assay inexpensive and easy to use in any lab that has basic PCR capabilities.
"Kathy and her team have been engaged with this and similar diagnostic technology for many years," said Mary Tapolsky, Senior Licensing Manager at the University of Colorado Technology Transfer Office.
Founded in 2003, InDevR is dedicated to the development and commercialization of innovative technologies that will help fill gaps in the current paradigm for virus-related diagnostics. The company plans to launch two products later this year: the Virus Counter for rapid virus quantification of viruses, and a pathogen detection platform based on low-density microarrays and novel signal amplification technology.